Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses elexacaftor-tezacaftor-ivacaftor and ivacaftor (Trikafta): Elexacaftor 100 mg–tezacaftor 50 mg–ivacaftor 75 mg (granules) and ivacaftor 75 mg (granules), oral Elexacaftor 80 mg–tezacaftor 40 mg–ivacaftor 60 mg (granules) and ivacaftor 59.5 mg (granules), oral Patients aged 6 years and older: Elexacaftor 50 mg–tezacaftor 25 mg–ivacaftor 37.5 mg (combination tablet) and ivacaftor 75 mg (tablet), oral Elexacaftor 100 mg–tezacaftor 50 mg–ivacaftor 75 mg (combination tablet) and ivacaftor 150 mg (tablet), oral. Indication: For the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.